Neurizon has appointed Dr Chris Bremer as chief executive as its NUZ-001 ALS program moves towards topline Phase 2/3 results expected in late Q2 2027. The incoming CEO brings more than 20 years of pharmaceutical and biotechnology experience, including over US$1 billion in licensing transactions.
- Dr Chris Bremer to become CEO on 1 October 2026
- NUZ-001 trial results expected in late Q2 2027
- More than 20 years of pharmaceutical and biotechnology leadership
- Over US$1 billion in licensing transactions executed
- A$450,000 fixed annual remuneration plus incentives
New CEO Arrives Before NUZ-001 Results
Neurizon Therapeutics Limited (ASX:NUZ; OTCQB: NUZTF) is changing leadership at one of the most consequential points in its ALS program, appointing Dr Chris Bremer as chief executive from 1 October 2026. His arrival comes as NUZ-001 advances through Regimen I of the registrational Phase 2/3 HEALEY ALS Platform Trial, with topline results expected in late Q2 2027.
The company says the trial includes 250 participants and that enrolment is complete. Bremer’s immediate remit will cover clinical and regulatory execution, capital and organisational readiness, and preparation for potential development, partnering and commercial pathways, subject to the study’s outcome. Those pathways remain prospective: NUZ-001 is investigational and is not approved for commercial use in any jurisdiction.
International Licensing Experience
Bremer spent about two decades at Grünenthal, holding senior commercial and global leadership positions that included responsibility for product launches, portfolio strategy, profit and loss management, and early-stage and commercial opportunities. He later served as the company’s interim chief commercial officer.
Neurizon says Bremer has executed more than US$1 billion in licensing transactions during his career. He has also held biotechnology leadership roles at Navigo Proteins and GAIASO Theranostics, spanning precision oncology, radiotheranostics and women’s health. His background combines medical and doctoral qualifications with an MBA from INSEAD, although the value of that experience for Neurizon will ultimately be tested against the clinical and regulatory milestones ahead.
Remuneration and Leadership Transition
Bremer will be based in Melbourne and will initially serve as CEO without joining Neurizon’s board. His fixed remuneration is A$450,000 a year, inclusive of statutory superannuation. The package includes a short-term incentive targeted at 30% of fixed remuneration, with a maximum of 50%, while the proposed long-term incentive has a target value equal to 100% of fixed remuneration and is expected to comprise performance rights and options, subject to approvals and performance conditions.
Interim Executive Chairman Sergio Duchini will move to the role of non-executive chair after Bremer starts and will work with him through the transition. The board has tied the incentive framework to measures expected to include clinical and regulatory execution, capital management, strategic and business development outcomes, and leadership performance. The next hard test is therefore not the appointment itself, but whether the new structure can carry Neurizon through the data release without losing focus on trial delivery or financial discipline.
Bottom Line?
Bremer gives Neurizon a commercially experienced leader before a major clinical catalyst, but the appointment cannot resolve the central uncertainty: whether NUZ-001 produces convincing results in late Q2 2027.
Questions in the middle?
- Will NUZ-001 deliver efficacy and safety results strong enough to support regulatory progress?
- How will Neurizon balance potential partnering opportunities with capital requirements before topline data?
- What performance conditions will govern the proposed long-term incentive package?